Gain Therapeutics Receives Approval To Commence Phase 1 Clinical Study Of GT-02287 From The Human Research Ethics Committee In Australia
Portfolio Pulse from Benzinga Newsdesk
Gain Therapeutics has received approval to commence Phase 1 clinical study of GT-02287 from the Human Research Ethics Committee in Australia. This is the first drug candidate identified with Gain's proprietary computational drug discovery platform SEE-Tx® to enter the clinical development phase.
September 12, 2023 | 1:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The approval for Phase 1 clinical study of GT-02287 could potentially boost Gain Therapeutics' stock as it marks a significant milestone in the company's drug development process.
The approval to commence Phase 1 clinical study of GT-02287 is a significant milestone for Gain Therapeutics. It validates the company's proprietary computational drug discovery platform SEE-Tx® and could potentially attract more investors, thereby driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100